rubius
therapeutics
announces
preclinical
data
supporting
lead
clinical
oncology
program
presented
society
immunotherapy
cancer
annual
meeting
cambridge
globe
newswire
rubius
therapeutics
nasdaq
ruby
biopharmaceutical
company
genetically
engineering
red
blood
cells
create
entirely
new
class
cellular
medicines
today
announced
company
present
preclinical
data
supporting
lead
clinical
oncology
program
upcoming
society
immunotherapy
cancer
sitc
anniversary
annual
meeting
meeting
held
virtually
november
allogeneic
red
cell
engineered
mimic
human
immune
system
stimulating
adaptive
innate
immunity
generate
immune
response
sitc
plan
present
preclinical
data
supporting
lead
clinical
oncology
program
demonstrating
promotes
cell
nk
cell
activation
expansion
vitro
vivo
said
laurence
turka
chief
scientific
officer
rubius
therapeutics
continuing
enroll
patients
phase
clinical
trial
treatment
patients
relapsed
refractory
locally
advanced
solid
tumors
cleared
investigational
new
drug
application
treatment
patients
relapsed
refractory
acute
myeloid
leukemia
actively
recruiting
posters
made
available
beginning
virtual
meeting
monday
november
et
throughout
poster
presentation
sessions
abstract
title
allogeneic
engineered
red
blood
cell
expressing
promotes
nk
cell
functionality
vitro
vivo
category
novel
immunotherapies
session
dates
times
november
et
poster
number
allogeneic
red
cell
engineered
mimic
human
immune
system
stimulating
adaptive
innate
immunity
generate
immune
response
simultaneously
presents
hundreds
thousands
copies
costimulatory
ligand
cytokine
native
forms
cell
surface
activate
expand
nk
cells
costimulatory
molecule
drive
nk
cell
proliferation
activation
interferon
gamma
ifnγ
production
cytokine
bridges
innate
adaptive
immunity
promoting
nk
cell
proliferation
nk
cell
cytotoxicity
fusion
receptor
alpha
rubius
therapeutics
rubius
therapeutics
biopharmaceutical
company
developing
new
class
medicines
called
red
cell
company
proprietary
red
designed
genetically
engineer
culture
red
cell
selective
potent
allogeneic
cellular
therapies
potential
treatment
several
diseases
across
multiple
therapeutic
areas
rubius
initial
focus
advance
product
candidates
treatment
cancer
autoimmune
diseases
leveraging
two
distinct
therapeutic
modalities
potent
interaction
tolerance
induction
rubius
therapeutics
manufacturing
site
recently
named
top
best
places
work
rhode
island
among
companies
providence
business
news
information
visit
follow
us
twitter
linkedin
like
us
facebook
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
statements
regarding
expectations
regarding
therapeutic
potential
red
cell
therapeutics
including
treatment
relapsed
refractory
locally
advanced
solid
tumors
acute
myeloid
leukemia
strategy
business
plans
focus
including
plans
present
preclinical
data
sitc
annual
meeting
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
risks
uncertainties
related
development
red
cell
therapeutic
product
candidates
therapeutic
potential
risks
identified
sec
filings
including
annual
report
form
year
ended
december
subsequent
filings
sec
caution
place
undue
reliance
statements
speak
date
made
disclaim
obligation
publicly
update
revise
statements
reflect
change
expectations
events
conditions
circumstances
statements
may
based
may
affect
likelihood
actual
results
differ
set
forth
statements
statements
contained
press
release
represent
views
date
hereof
relied
upon
representing
views
subsequent
date
explicitly
disclaim
obligation
update
statements
contacts
investors
lori
melançon
vice
president
corporate
communications
investor
relations
media
marissa
hanify
director
corporate
communications
dan
budwick
dan
